We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US private biotech Cancer Prevention Pharmaceuticals has filed a marketing application in Europe for CPP-1X/sul, a preventative treatment for patients with familial adenomatous polyposis (FAP).